Immunohistochemistry is a technique used to detect antigens or biomolecules in cells of a tissue section by exploiting the principle of antibodies binding specifically to antigens in biological tissues. Immunohistochemistry helps in diagnosis of various cancers like breast cancer, prostate cancer, gastric cancer, and others. It also aids in pathophysiological analysis of diseases and allows visualization of biomarkers in situ in morphologically preserved tissues.
The global immunohistochemistry market is estimated to be valued at US$ 2.88 billion in 2024 and is expected to exhibit a CAGR of 6.5% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the immunohistochemistry market are Merck KGaA, Rockland Immunochemicals Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, PerkinElmer Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Bio SB, Agilent Technologies Inc., Abcam plc., Becton Dickinson and Company, Miltenyi Biotec, Biocare Medical LLC, Eagle Biosciences Inc., Bio-Techne, Diagnostic Biosystems Inc., and BioGenex. The key opportunities in the market include increasing healthcare expenditure and rising awareness regarding disease diagnosis. North America is expected to dominate the immunohistochemistry market during the forecast period owing to presence of major market players and advanced healthcare infrastructure in the region. Market Drivers The Immunohistochemistry Market Demand is driven by the rising incidence of chronic diseases such as cancer owing to changing lifestyle habits and increasing geriatric population globally. According to WHO, cancer burden rose to 19.3 million new cases and 10 million cancer deaths in 2020. Moreover, technological advancements in IHC instruments such as fully automated slide strainers and digital pathology systems are further contributing to market growth. Growing application of IHC in research activities to understand disease pathology at molecular level also supports market expansion over the forecast period.
PEST Analysis: Political: Regulations related to healthcare expenditure, insurance coverage, reimbursement guidelines, medical device approvals influence the market. Stringent approval processes can delay market launches. Economic: Rising healthcare expenditure, growing biotechnology industry, increasing focus on cancer and infectious disease research drive market growth. However, budget cuts can affect funding availability for R&D. Social: Growing awareness about disease diagnosis and rising cases of cancer and infectious diseases increase demand. Aging population promotes early detection needs. Technological: Advancements in imaging technologies, staining techniques, automated analysis systems improve diagnostic capabilities. Adoption of digital pathology and AI/ML applications in immunohistochemistry expand market opportunities. The geographical regions where the market is concentrated in terms of value are North America and Europe. North America holds the largest market share due to advanced healthcare infrastructure and high disease burden. developed research capabilities and availability of funding for research activities drive market growth in these regions. The fastest growing region for the immunohistochemistry market is Asia Pacific. Factors such as improving healthcare infrastructure, increasing healthcare expenditure, rising diagnostic needs due to growing geriatric population, and favorable government policies foster market growth in Asia Pacific. Emerging economies are witnessing heavy foreign investments and developing R&D capabilities. This increases diagnostic assay adoption and regional market expansion.
Get more insights on Immunohistochemistry Market
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
